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Bio-pharmaceutical R&D is increasingly an international affair. Research articles published in 
the peer-reviewed international scientific and technical journals represent quantifiable research 
outputs of bio-pharmaceutical firms. Large-scale systemic measurements of worldwide trends and 
sectoral patterns within bio-pharmaceutical science can be gauged from these articles, where co-
authored research papers are assumed to reflect research cooperation and associated knowledge 
flows and exchanges. We focus our attention on the largest science-based multinational enterprises 
(MNEs), those that produce relatively large quantities of research articles. The study deals with the 
worldwide output of research articles that are co-produced by corporate researchers during the 
years 1996–2001.  
We employ these publications to examine structural factors characterizing research 
cooperation networks within industry at the level of major geographical regions (North America, 
Europe, Pacific-Asia), with a breakdown by within-MNE and between-MNE network linkages. 
The descriptive statistics on publication output and results of network analyses of co-publication 
linkages not only indicate regional differences, with a central role for US companies in bio-
pharmaceutical research, but also a variety of firm-specific research cooperation networks which 
enabled us to develop a tentative typology of MNEs in terms of their intra- and inter-
organizational patterns of research cooperation linkages.  
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Introduction 
Many of the largest bio-pharmaceutical firms face spend approximately 15% of their 
sales on R&D; in some cases their annual R&D costs amount to billions of euros. The 
globalization of markets, the regionalization of technical and scientific knowledge, 
scientific progress in the biomedical sciences, and the complexity of drug discovery 
processes, are forcing these companies to disperse their R&D organization and engage 
increasingly in R&D partnerships to access all the required knowledge and 
technologies. At the same time, as HOWELLS (1990) points out, modern information and 
communication technologies serve to connect disseminated R&D activities and thus 
made distributed R&D organization possible. Because the bio-pharmaceuticals sector is 
often leading the way in this process of internationalization in their continual search for 
applicable knowledge and first-rate partners for their drug discover research, we are 
going to focus our attention on the large science-based multinational enterprises 
(MNEs) that are active in the bio-pharmaceuticals sector and produce relatively large 
numbers of research articles – either with partners within the MNE and/or with external 
partners within the private sector. 
During the last two decades, the bio-pharmaceuticals industry has shifted its basic 
research operations from trial-and-error drug discovery approaches to a more science-
based deductive method of searching for new target receptors and molecules that inhibit 
the target (e.g. ARORA & GAMBARDELLA, 1994; HENDERSON & COCKBURN, 1994; 
NIGHTINGALE, 2000). As a result, the ties between biotechnology companies and bio-
pharmaceuticals companies have become close, and new organisational forms emerged 
to conduct basic bio-pharmaceutical research. 
Traditionally a MNE’s most strategic ‘core’ research activities were concentrated in 
a central R&D laboratory which was usually located in the home country. Nowadays, 
these elaborate organizational structures to enable research collaborations are 
determined and influenced by a wide range of factors, including the company’s internal 
distribution and allocation of R&D resources (GASSMANN & VAN ZEDTWITZ, 1999; 
2002), access to locally based technological expertise (CANTWELL & JANNE, 2000), the 
role of local or national governments in partnership promoting initiatives, as well as 
business strategies impacting on the propensity towards cooperation; outsourcing of 
research, or engaging in both horizontal (within-MNE) or vertical (external) research 
collaboration. 
Clearly there are immense methodological problems in systematically analysing the 
organizational and geographical characteristics of R&D activities by MNEs. Measuring 
and comparing their research cooperation networks is notoriously difficult. Many of 
these measurement problems relate to the scale, and levels of importance, of research 
cooperation, and the ways in which the objectives of research cooperation and networks 
can change over time. A solution for this dilemma is the application of empirical 
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evidence extracted from the contents of scientific and technical articles that are authored 
industrial researchers and published in the peer-reviewed international scientific and 
technical journals. Although companies may publish for a large variety of reasons 
(TIJSSEN, 2004), one of which is to leverage results of their research as an interface to 
the global research community (HICKS, 1995), in most cases these articles reflect 
knowledge creation and knowledge transfer processes within corporate research labs.1 
The affiliate addresses of the author(s) listed on these research articles enable 
comparative analyses at the level of individual companies and their countries of location 
(e.g. TIJSSEN et al., 1996; GODIN, 1996). Especially the big pharma companies publish 
sufficiently large annual quantities of research articles in the journal literature to 
warrant company-level (trend) analyses of research output related characteristics. A 
score of empirical studies have drawn on publication counts as an important indicator of 
research activity in the pharmaceutical industry (e.g. KOENIG, 1983; NARIN & ROZEK, 
1988; GAMBARDELLA, 1995; MCMILLAN & HAMILTON, 2000; COCKBURN et al., 2000; 
D’ESTE, 2005). 
A significant share of industry’s research articles list co-authors based at other 
affiliations within the same (parent) company, other companies, and/or public research 
organizations. This information source also enables aggregate-level quantitative 
information on patterns of research collaboration and related knowledge-spillovers.2 
We use these co-publications to examine structural factors that impact on research 
cooperation within and between companies. These research cooperation networks can 
be examined systemically by creating connectivity indicators based on these co-
publications, thus showing relationships and linkages between the various actors and 
agents involved in joint scientific research. The network analyses of co-publication 
linkages indicate structural differences between types of MNEs, which enabled us to 
develop a general typology of MNEs in terms of their patterns of research cooperation 
linkages.  
Data collection and methodology 
The research publications that were analysed for this study were extracted from 
CWTS’s Corporate Research Papers (CRP) database, a subset of research articles 
published in international scientific and technical journals that are covered by the 
                                                          
1
 This source of printed ‘codified knowledge’ not only reflects “discovery” research done with the labs of the 
bio-pharmaceutics companies, but also related experience-based ‘tacit’ knowledge and the related skills base 
(e.g. MOWERY et al., 1996). 
2
 Co-authoring scientific publications is one of the clearest links to informal networking that can be made. 
These joint research papers reflect successful scientific co-operation and are likely to signify related 
knowledge flows and research networking activity between companies. Nevertheless, co-publication statistics 
and indicators should be handled with due care as a reliable source of conclusive empirical evidence on actual 
scientific cooperation (e.g. KATZ & MARTIN, 1997).  
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CWTS-licensed CD-Rom Edition of Thomson Scientific’s Citation Indexes, in which at 
least one of the affiliate addresses of the authors refers to a private sector organization 
(see Tijssen, 2004).3 A co-authored paper is fully credited to all firms listed in the 
author address information.4,5 The bio-pharmaceuticals companies included in this 
study were selected according to their presence of at least one of their business unit or 
subsidiaries in Dunn & Bradstreet’s “Who owns Whom” database (edition 2003), and 
the (parent) company’s volume of (co-authored) research articles that were indexed in 
the CRP database. First, all business units/subsidiaries with Standard Industrial Code 
(SIC) code 2834 (“Drugs”) were selected.6 Then, all the (parent) companies of those 
business units/subsidiaries were selected that published at least five research articles 
during the years 1996–2001.7 The companies that are represented in this set of 
publications were mostly (very) large pharmaceutical firms, especially the MNEs that 
invest heavily in their own research capabilities and sustain R&D labs that also perform 
original cutting-edge scientific research. One of the main characteristics of this set of 
papers is that 55.6% of the publications where produced by companies located in North 
America, including the Canadian companies.8 
Each standardised name of the (parent) company was linked to the country of the 
company’s location, i.e. the country of origin listed in the author affiliate address 
information in the research article. These company/country pairs enabled us to identify 
                                                          
3
 The CRP includes some 350,000 research papers published in 1996–2005 and (partially) assigned to the 
private sector. The coverage extends across all countries and fields of science and some 40,000 different main 
organizations are covered. Foreign branches and foreign subsidiaries of multinational companies are labelled 
with the consolidated name of the parent company. Companies that were added to the parent company 
through mergers and acquisitions were renamed to the current (ultimate) parent company to ensure backwards 
and forwards compatibility in trend analyses.  
4
 Dividing a paper between the participating units (researchers, organizations, countries) is to some extent 
arbitrary – there is no fair method to determine how much money, effort, equipment and expertise each entity 
contributes the underlying research effort and writing the paper. Our basic assumption therefore is that each 
author, and associated corporate affiliate, made a non-negligible contribution.  
5
 All co-publications are treated similarly in the statistical analyses, irrespective of the number or type of 
organisations (private or public sector) listed in the author address information. As a result, a co-publication 
listed two or more different (parent) companies may or may not include addresses referring to public sector 
organisations.  
6
 Given the variety of SIC codes assigned to the different business units of the same (parent) company, many 
corporate affiliates were therefore allocated to several of the industrial sectors. The selection and matching 
procedure was carried out by CWTS in cooperation with CESPRI (Bocconi University, Milan, Italy).  
7
 The data for this study were taken from the European project ‘Network Indicators: Science, Tecnology and 
Innovation (STI-NET)”. The STI-NET Project started on January 15th 2002 and was a 30 months project. The 
partners were CESPRI – Centre for Research on Innovation and Internationalisation Processes, Università 
Luigi Bocconi, Italy, MERIT – Maastricht Economic Research Institute on Innovation and Technology, 
University of Limburg, The Netherlands and the CWTS – The Centre for Science and Technology Studies, 
University of Leiden, The Netherlands. The aim of the research project was the identification, construction, 
and analytical use of network indicators in science, technology and innovation.  
8
 For comparison, the US accounted for 31% of all research publications worldwide across all fields of 
science in 1998 and 2001 (EC, 2003), considerably less than its 55.6% share of corporate research papers in 
the bio-pharmaceutical industry.  
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separate national affiliates of the (parent) companies (e.g. “Bayer AG/Germany” and 
“Bayer Corp/USA”), either the company headquarters in the home country or foreign 
subsidiaries. These company-country combinations are referred to as “corporate 
affiliates” hereafter. This breakdown by country enabled us to analyze and interpret co-
publication data both in terms of intra-organizational collaboration (within the parent 
company “Bayer”) as well as inter-organizational research partnerships (between 
different parent companies). 
The last step to get the final core set of publications was to extract from the CRP 
database all the research papers that list at least two addresses referring to two selected 
corporate affiliates. The companies that took part on this set of publications were mostly 
(very) large pharmaceutical firms, especially MNEs. In total, there were 378 corporate 
affiliates. The resulting co-publication frequencies for each pair of affiliates were 
collected in a data array that was fed into the UCINET software package (BORGATTI et 
al., 2002) that performs a network analysis providing statistics and graphical 
representations of the network structure. 
Main results 
Distribution of co-publication partnerships by region 
Using the geographical distribution of research partners listed on joint research 
papers, either within the same (ultimate) parent firm, or between firms, enabled us to 
estimate the degree of internationalization of corporate research cooperation. The 
breakdown by broad geographic region in Table 1 indicates that corporate research 
partnering within the pharmaceutical sector has become truly globalized at the end of 
the 20th century. Not only, do we also observe a particularly large propensity for tri-
partite cooperation, with partners spread across three regions, which account for 15% of 
the co-publications, we also find 8% of the co-publications listing partners in four 
different regions. The majority of the relationships across three of four regions refer to 
connections between North America, EU-15, and the Other European countries, the 
latter being largely a result of large MNEs based in Switzerland.  
How can this degree of globalization and these geographical variations be 
explained? The above findings are obviously significantly affected by the 
geographically diversified science-based MNEs with R&D-labs scattered around the 
globe. Overall, we find a dominant role of North American companies in the trans-
region research cooperation, which is in part due to the attractive assets offered by US 
biotechnology companies in terms of their information sources, new approaches and 
advanced capabilities.9 
 
                                                          
9
 One of the major strengths of the US bio-pharmaceuticals industry lies in its specialization in bio/gene 
technologies for drug discovery in the fields of immunology and oncology. 
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Table 1. Corporate co-publication partnerships by number of regions involved, 
1996–2001 
Location of research partners Share of all co-publications (%) 
Within regions – total 46 
Within North America (NA) 24 
Within Europe – EU-15 12 
Within Pacific Asia 10 
Within Europe-Others 0 
  
Two regions – total 31 
NA + EU-15 18 
NA + Pacific Asia 5 
NA + Europe-Others 2 
EU-15 + Europe-Others 3 
EU-15 + Pacific Asia 3 
  
Three or four regions – total 23 
NA + EU-15 + Europe-Others 9 
NA + EU-15+Europe-Others + Pacific Asia 7 
NA + EU-15 + Pacific Asia 6 
NA + Europe-Others + Pacific Asia 1 
 
This geographically diversified science-base is also influenced by the scattering of 
the research performing companies. Out of a total of 378 affiliates: 42% were North 
American-based; 37% were located in EU-15 countries; 18% in the Pacific Asia region 
(mainly Japan and Taiwan, and excluding Australia); 2% were based in ‘Other 
European countries’, principally in Switzerland, Norway, and Israel,10 and only 1% 
were assigned to ‘other countries’ which refers to companies located in Australia.  
The main determining factor for the North American surplus and deficits of co-
publication outputs by the other regions clearly the size of the (science-related) 
industrial base of each region. In terms of sheer magnitude, we note the marked 
dominance of North American-based affiliates (US and Canada) as a consequence from 
the combination of several factors: (1) the size of US industry in the sectors, (2) the 
scale of their research activity, (3) their propensity for research cooperation, (4) their 
propensity to publish research findings in the open scientific literature. These factors are 
obviously difficult to unravel empirically at an aggregate level, let alone at the company 
level, a second explanatory determinant can be gleaned from further breaking down the 
partnerships geographically. 
                                                          
10
 Israel was considered an European country in this study.  
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Table 2 exhibits the breakdown of co-publications by geographic location of 
research partners. First, we observe a strong tendency towards corporate research 
partnering within the region. The majority of the co-publication partners of each of the 
major regions (North America, Europe, and Pacific Asia) are located within the same 
region, which is to a large degree the logical consequence of proximity effects due to 
common (domestic) research systems, share language and culture, or the regional scope 
of business activities. However, we do find a relatively low share of within-region 
partnerships within the EU-15 in comparison to North America, which suggests that the 
European pharmaceutical industry less affected by proximity effects. One of the reasons 
for this difference is the US-orientation of the large Swiss bio-pharmaceutical MNEs 
(for example Novartis, which is further discussed in the next section). Interestingly, 
these non-EU-15 companies prefer North America partners even more than EU-15 
counterparts. Another possible explanation for Europe’s extra-regional orientation 
relates to the presence of affiliates of non-European MNEs within Europe; these foreign 
affiliates tend to engage in intra-MNE cooperation with other affiliates located outside 
Europe (as illustrated in the examples provided in the next section).  
 
Table 2. Within-region and between-region research collaboration between corporate affiliates 1996–2001 
(row percentages) 
 % within-region    % partners in other regions   
Location of affiliate    partnerships   NA EU-15 Europe-Other Pacific Asia Other 
North America (NA) 75  16 4 2 3 
Europe – EU-15 52 37  8 3 0 
Europe – Other 12 48 37  4 0 
Pacific Asia 66 19 12 3 0 0 
 
When analyzing the intra-MNE organisational dimension of research networks, size 
does seem to matter. Considering their large share of the corporate research literature 
worldwide, the US-based affiliations seem to have relatively many domestic partners. 
The domestic orientation of the USA is in part explained by the scale and diversity of 
the US corporate sector, which comprises of an almost self-contained R&D base. We 
find a significant overrepresentation of the EU-15-based affiliates in research 
partnerships, which is in large part due to the European affiliates of US companies. 
Remarkable is the relatively small share of partnerships between North America and the 
companies in Pacific Asia. This deviant result might reflect cultural differences, where 
Western companies tend to adopt relatively “open” R&D models with international 
cooperative structures whereas MNEs with headquarters based in Japan and South 
Korea prefer more “closed” structures that favour cooperation across close geographic 
proximities. In contrast, the EU-15 based MNEs are much less regionally focused. Next, 
we observe remarkably low intra-regional cooperation propensities within the affiliates 
based in the Other European countries, which is no doubt due to the small size of the 
domestic industrial base – hence, few (potential) research partners – and partially a 
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result of the industrial sector structure which is dominated by a few large multinational 
affiliates with branches and R&D labs worldwide (e.g. Swiss-based pharmaceutics 
companies).  
Research collaboration network patterns 
Only 35 companies (accounting for 129 corporate affiliates) are in fact MNEs 
exhibiting co-publication links between their various affiliations (i.e. company 
headquarters and subsidiaries/branches in different countries). The remainder comprises 
multinational enterprises with only one research facility or R&D laboratory that is 
producing research papers, and national enterprises with no foreign affiliations. Starting 
from the arrays of co-authorship frequencies, the co-publication linkages between the 
MNE’s headquarters and its foreign subsidiaries are identified and the various nodes 
(circles), each representing corporate affiliates, are connected. Each link between the 
nodes indicates one or more co-authored research publications. Co-publication links to 
affiliates of other companies are represented by squares.  
Focusing on the structural features of the co-publication patterns of those 31 
‘networked’ MNEs, we identify three general types of co-publication networks 
characterizing the relationships between headquarters and subsidiaries of the same 
company: (1) centralized networks, (2) decentralized networks, and (3) gateway 
networks.  
Centralized corporate research network. This particular kind of network consists of 
co-publications involving the company headquarters (i.e. central R&D laboratory) and 
its affiliates, as well as their co-publishing activity with other companies that tend to 
concentrate at the company headquarters. This set includes 14 MNEs. Figure 1 displays 
an illustrative example of this type of centralized network for the case of Bayer. All of 
Bayer’s subsidiaries co-published with the headquarters in Germany, as well as with 
Bayer labs in the USA. The headquarters, USA and Great Britain all have research 
collaborations with other firms based in the EU-15, in other European countries and in 
North America. Bayer/Japan extends this network with additional collaborations with 
companies in its own region. 
Decentralized corporate research networks. This category comprises of networks 
that are characterized by the lack of (strong) links between the company headquarters 
(i.e. central research laboratory) and subsidiaries that do not co-publish. Rather, each 
research laboratory co-publishes with other companies located in the different regions 
of the globe. The pattern reflects a corporate R&D strategy with geographically 
dispersed and (semi) autonomous research laboratories. About 14 of the 31 MNEs can 
be attributed to this category. Figure 2 shows then network of Novartis. Novartis’ head-
quarters are located in Switzerland with several subsidiaries scattered across the globe. 
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Figure 1. Centralized corporate research network: Bayer 
Circles – Country of location of corporate affiliates belonging to the same multinational enterprise. 
Squares – Region of location of external partners in research co-publications. 
The thickness of the connecting line indicates the quantity of co-publications 
 
Figure 2. Decentralized corporate research network: Novartis 
Circles – Country of location of corporate affiliates belonging to the same multinational enterprise. 
Squares – Region of location of external partners in research co-publications. 
The thickness of the connecting line indicates the quantity of co-publications 
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Novartis Switzerland is connected with all regions, with an especially strong link to 
Novartis’ operations in the EU-15 and the North America region. We can see how each 
of the subsidiaries have their own pattern of collaboration, sometimes focused on EU-
15 and North America region, as the case of Novartis’ research in Netherlands, Italy, 
France, while others focus more on Pacific Asia and North America region, like in the 
case of Novartis research activities in Japan. 
Gateway corporate research network. This kind of network is characterized by 
researchers and scientists at the company’s subsidiaries co-publishing exclusively with 
their colleagues based at headquarters/central R&D facility, while the latter also co-
publish with external partners. Only a small minority of the 31 companies appears to 
operate through these gateway networks. This rare kind of network is characterized by 
researchers and scientists at the company’s subsidiaries co-publishing exclusively with 
their colleagues based at headquarters/central R&D facility, while the latter also co-
publish with external partners. Figure 3 displays the example of Baxter Healthcare, a 
US company with two subsidiaries that run research facilities – Baxter Germany and 
Baxter Belgium. Each subsidiary co-publishes with their headquarters, which in turn co-
publishes also with other companies located elsewhere, North America and EU-15.  
 
 
Figure 3. Gateway corporate research network: Baxter 
Circles – Country of location of corporate affiliates belonging to the same multinational enterprise. 
Squares – Region of location of external partners in research co-publications. 
The thickness of the connecting line indicates the quantity of co-publications 
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Discussion and concluding remarks 
This empirical study set out to explore the analytical potential of corporate research 
articles as a source of empirical information for describing structural patterns of 
research joint ventures (RJVs) within the bio-pharmaceutical industry worldwide, and 
to produce quantitative data on those research cooperation relationships at the level of 
countries and major bio-pharmaceutical firms. Given the overwhelming significance of 
basic research in the bio-pharmaceutical industry, and the large quantity of corporate 
research papers produced each year, we believe than these publications reflect key 
characteristics of research cooperation patterns within the industry. The pivotal position 
of the USA in the bio-pharmaceuticals research output, and the associated global 
research network, is not surprising in view of the US dominance in the bio-
pharmaceutical sector. More interesting is the particularly strong link we observe 
between US companies and their research partners in EU-15 countries – either with 
overseas affiliations of these US companies or external partners. At the firm level, we 
discerned two types of links: (1) those amongst corporate affiliations belonging to the 
same (parent) company, and (2) linkages between affiliations of different (parent) 
companies. The outcome revealed interesting empirical information both with respect to 
the organizational features of corporate research partnerships within and between 
companies, as well as geographical dispersion of these partnerships. The company-level 
breakdown of these cooperation patterns also reveals a variety of intra-firm and extra-
firm research linkages, from which three main types of corporate research networks can 
be derived in terms of the intra-firm distribution of research partnerships: (a) centralized 
networks, (b) decentralized networks, and (c) gateway networks. The first two types 
seem to be by far the most common ones.  
It stands to reason that the various types of within-firm linkages are driven by 
different corporate “logic” governed by the prevailing R&D objectives and constraints, 
intellectual property rights and knowledge appropriation regimes, and research 
cooperation motives. Moreover, some of the large pharmaceutical companies nowadays 
adopt “open” innovation structures, where R&D cooperation and networking both 
within and outside the company become increasingly integrated, especially between 
‘big pharma’ companies and smaller biotechnology companies (a recent example is the 
relationship between Roch, the Swiss company, and the UK biotech firm Antisoma). 
The joint research publications emerging from these pharma-biotech RJVs have not 
been included in this study owing to the relatively low numbers of papers. 
It is also important to note that many of these research partnerships, and the 
corresponding co-publications, may also include partners from public sector research 
organisations and universities (TIJSSEN, 2004). These contributions were not included in 
the network analysis presented in this paper and are left to future research. Nonetheless, 
the presence of public sector researchers in ‘corporate’ RJVs raises questions about the 
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nature of the research links between the various corporate affiliations; to what degree 
these were predominantly curiosity-driven ‘academic’ partnerships, industry-driven 
‘application-oriented’ partnerships, or a mixture of both? Each type of collaboration is 
likely to operate according to their own rationale, with different sets of (ultimate) goals 
and deliverables. Generally speaking, these joint research articles should be viewed as 
reflecting research cooperation at the work floor level. As such, they are more likely to 
describe ‘informal’ research linkages and networking processes between individual 
researchers, rather than representing the key results of ‘formalised’ and targeted 
alliances between R&D departments or research teams within firms. As a consequence, 
the structural characteristics of co-publication networks, as depicted in our graphs, are 
therefore not likely to correspond or correlate with senior management’s view of its 
networking activity in the same way as linkages based on corporate R&D alliances. We 
would argue that a publications-based view of corporate research is in fact one of the 
strengths of our approach, in the sense that it helps external analysts get closer to the 
joint research products emerging from the day-to-day operations of scientists and 
technicians employed by the research labs of the bio-pharmaceutical companies. 
To conclude, although our empirical data shed some light on corporate research 
partnering in the bio-pharmaceutical industry, especially within large science-intensive 
multinational enterprises, we still know little about the detailed and hard-to-observe 
mechanisms and organizational conditions giving rise to research articles produced by 
corporate researchers in collaboration with colleagues. Case studies of individual 
pharmaceutical companies, such as recent studies conducted by CRISCUOLO & NARULA 
(2005) or CRISCUOLO (2005), constitute important next steps to help gain inside-
information to unravel the country-specific, firm-specific and person-specific 
determinants that impact on the reasons for engaging in research cooperation and the 
propensity to produce the (joint) research articles we have analyzed in this study.  
* 
Part of research described in this paper relates to the STI-NET project that was funded by European 
Commission [Contract HPV2-CT2001-00014] in which CESPRI (Univ. Bocconi, Milan, Italy), MERIT 
(Univ. Maastricht, Netherlands) and CWTS participated. 
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